MLSSMilestone Scientific Inc.
Is Milestone Scientific struggling financially?
Yes, by its own account. Milestone Scientific told the SEC on 13 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed May 2026
30/100
Fragile
- Sector
- Biotech/Pharma
- Market cap
- $42.7M
- Source filing
- 10-Q 13 May 2026
- Balance sheet
- 30 Jun 2026
Cash runway
Not estimable
The latest filings do not carry the cash or cash-flow lines needed to estimate a runway. Publishing a number here would mean inventing one.
What it reported
Cash burned over the last 12 months
$2.9M
What Milestone Scientific told the SEC
…2025, we had cash flows provided by (used in) operating activities of approximately $ 0.1 million and $ ( 1.0 ) million, respectively. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. On April 20, 2026, the Company completed a private placement of 7,962,963 units at a purchase price of $ 0.27 per unit, generating gross proceeds of approximately $ 2.15 million,…
Milestone Scientific Inc., Form 10-Q, filed 13 May 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- Cash burn is narrowing It is spending 56% less cash per year than it was, so the runway above is lengthening rather than shortening.
Other Biotech/Pharma companies that filed the doubt
- JUNS Jupiter Neurosciences $4.8M
- LABT Lakewood-Amedex Biotherapeutics $5.3M
- MCRB Seres Therapeutics $45.8M
- MOBI Mobia Medical $353.2M
- PIII P3 Health Partners $74.9M
- PLYX Polaryx Therapeutics $103.2M